Lisdexamfetamine Dimesylate Capsules Solicitation
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has issued a Solicitation for a national supply source of Lisdexamfetamine Dimesylate Capsules. This opportunity, identified as SPE2D2-26-D-0004, seeks to establish a firm-fixed-price requirements contract for various dosages and bottle counts. The award will be made to the responsible offeror with a technically acceptable proposal and the lowest evaluated aggregate price. Offers are due July 2, 2026, at 3:00 PM ET.
Scope of Work
This solicitation requires the provision of Lisdexamfetamine capsules in 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, and 70 MG dosages, supplied in both 90-count and 100-count bottles. Key requirements include:
- Manufacturing & Compliance: Facilities must maintain acceptable current Good Manufacturing Practices (cGMP) status with the FDA. Products must comply with the Drug Supply Chain Security Act (DCSA).
- Labeling & Packaging: Products need bar code labeling (GS1-128 or similar), compatibility with automated dispensing units, and child-proof closures with specific bottle dimensions. Unit of use packaging is mandatory.
- Product Registration: Offerors must ensure product information is registered with RXNorm, First Data Bank, and Medi-Span prior to contract performance.
- Trade Agreements: Identification of the Country of Origin for end products and active pharmaceutical ingredients is required.
Contract Details
- Contract Type: Firm-fixed-price requirements contract.
- Period of Performance: One base year with four option years, for a maximum potential term of five years.
- Contract Price Effective Date: No more than 60 calendar days after award.
- Contract Performance Date: 45 calendar days after award (or sooner by mutual agreement).
- Set-Aside: This acquisition is UNRESTRICTED. Offerors must represent their small business status.
Submission & Evaluation
- Submission Method: Offers must be submitted electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS).
- Proposal Structure: Proposals must be organized into two volumes: Volume 1 (Non-Price Proposal) and Volume 2 (Price Proposal).
- Evaluation Basis: Award will be made on a Lowest Price Technically Acceptable (LPTA) basis. Proposals will be evaluated on Technical Requirements and Past Performance. The lowest evaluated aggregate price will be the determining factor for award.
- Key Deadlines: Offers are due by July 2, 2026, at 3:00 PM ET.
Additional Notes
The solicitation includes provisions for a Reverse Auction (RA). Offerors must comply with all Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses. A cost recovery fee of 0.5 percent of the contract price is required. Appendices A and B provide lists of current Pharmaceutical Prime Vendors (PPVs) and Agency Annual Demand Projections, respectively.